SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Aandahl A)
 

Sökning: WFRF:(Aandahl A) > (2015-2017) > Adverse events in a...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006695naa a2201021 4500
001oai:DiVA.org:umu-120207
003SwePub
008160511s2016 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:fbe5c160-409e-4caf-b214-8c34e5f23409
009oai:DiVA.org:liu-135128
024a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1202072 URI
024a https://doi.org/10.1016/j.transci.2016.01.0032 DOI
024a https://lup.lub.lu.se/record/85774142 URI
024a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1351282 URI
040 a (SwePub)umud (SwePub)lud (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
100a Mörtzell Henriksson, Monicau Umeå universitet,Medicin,Nephrol, Umeå, Sweden4 aut0 (Swepub:umu)momo0019
2451 0a Adverse events in apheresis :b an update of the WAA registry data
264 1b Elsevier,c 2016
338 a electronic2 rdacarrier
520 a Apheresis with different procedures and devices are used for a variety of indications that may have different adverse events (AEs). The aim of this study was to clarify the extent and possible reasons of various side effects based on data from a multinational registry. The WAA-apheresis registry data focus on adverse events in a total of 50846 procedures in 7142 patients (42% women). AEs were graded as mild, moderate (need for medication), severe (interruption due to the AE) or death (due to AE). More AEs occurred during the first procedures versus subsequent (8.4 and 5.5%, respectively). AEs were mild in 2.4% (due to access 54%, device 7%, hypotension 15%, tingling 8%), moderate in 3% (tingling 58%, urticaria 15%, hypotension 10%, nausea 3%), and severe in 0.4% of procedures (syncope/hypotension 32%, urticaria 17%, chills/fever 8%, arrhythmia/asystole 4.5%, nausea/vomiting 4%). Hypotension was most common if albumin was used as the replacement fluid, and urticaria when plasma was used. Arrhythmia occurred to similar extents when using plasma or albumin as replacement. In 64% of procedures with bronchospasm, plasma was part of the replacement fluid used. Severe AEs are rare. Although most reactions are mild and moderate, several side effects may be critical for the patient. We present side effects in relation to the procedures and suggest that safety is increased by regular vital sign measurements, cardiac monitoring and by having emergency equipment nearby.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a Apheresis
653 a Adverse events
653 a Plasma
653 a Albumin
653 a Donor
653 a Adverse events
653 a Albumin
653 a Apheresis
653 a Donor
653 a Plasma
700a Newman, Eu Bone Marrow Transplant and Apheresis, New South Wales, Australia4 aut
700a Witt, Vu St. Anna, Vienna, Austria4 aut
700a Derfler, Ku AKH, Vienna, Austria4 aut
700a Leitner, Gu AKH, Vienna, Austria4 aut
700a Eloot, Su Gent, Belgium4 aut
700a Dhondt, Au Gent, Belgium4 aut
700a Deeren, Du Roeselar, Belgium4 aut
700a Rock, Gu Canada4 aut
700a Ptak, Ju Frydek-Mistek, Czech Republic4 aut
700a Blaha, Mu Hradec Kralove, Czech Republic4 aut
700a Lanska, Mu Hradec Kralove, Czech Republic4 aut
700a Gasova, Zu Prague, Czech Republic4 aut
700a Hrdlickova, Ru Ostrava, Czech Republic4 aut
700a Ramlow, Wu Rostock, Germany4 aut
700a Prophet, Hu Rostock, Germany4 aut
700a Liumbruno, Gu Livorno, Italy4 aut
700a Mori, Eu Livorno, Italy4 aut
700a Griskevicius, Au Vilnius, Lithuania,BC, Umeå, Sweden4 aut
700a Audzijoniene, Ju Vilnius, Lithuania4 aut
700a Vrielink, Hu Amsterdam, The Netherlands4 aut
700a Rombout, Su Maastricht, The Netherlands4 aut
700a Aandahl, Au Oslo, Norway,Skopje, Macedonia,Nephrol., Karlstad, Sweden4 aut
700a Sikole, A4 aut
700a Tomaz, Ju Coimbra, Portugal4 aut
700a Lalic, Ku Belgrade, Serbia4 aut
700a Mazic, Su Zagreb, Croatia4 aut
700a Strineholm, Vu Orebro, Sweden4 aut
700a Brink, Bu Huddinge, Sweden,Nephrol, Umeå, Sweden,Nephrol., Skövde, Sweden4 aut
700a Berlin, Göstau Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Klinisk immunologi och transfusionsmedicin4 aut0 (Swepub:liu)gosbe95
700a Dykes, Josefinau Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Lund, Sweden4 aut0 (Swepub:lu)efor-jdy
700a Toss, Fu BC, Umeå, Sweden4 aut
700a Axelsson, C G4 aut
700a Stegmayr, Berndu Umeå universitet,Medicin4 aut0 (Swepub:umu)best0006
700a Nilsson, Tu Nephrol, Uppsala, Sweden4 aut
700a Norda, Ru BC, Uppsala, Sweden4 aut
700a Knutson, Fu BC, Uppsala, Sweden4 aut
700a Ramsauer, Berndu Skövde4 aut0 (Swepub:umu)bera0016
700a Wahlström, A4 aut
710a Umeå universitetb Medicin4 org
773t Transfusion and apheresis scienced : Elsevierg 54:1, s. 2-15q 54:1<2-15x 1473-0502x 1878-1683
856u https://doi.org/10.1016/j.transci.2016.01.003y Fulltext
856u https://umu.diva-portal.org/smash/get/diva2:927154/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
856u http://www.trasci.com/article/S1473050216000057/pdf
856u http://www.ncbi.nlm.nih.gov/pubmed/26776481?dopt=Abstractx freey FULLTEXT
856u http://dx.doi.org/10.1016/j.transci.2016.01.003x freey FULLTEXT
856u https://liu.diva-portal.org/smash/get/diva2:1079874/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-120207
8564 8u https://doi.org/10.1016/j.transci.2016.01.003
8564 8u https://lup.lub.lu.se/record/8577414
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-135128

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy